(Total Views: 650)
Posted On: 09/13/2021 6:00:52 AM
Post# of 153993
VANCOUVER, Washington, Sept. 13, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"
, a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer and Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development of CytoDyn will provide a comprehensive business update at the upcoming Emerging Growth Conference. CytoDyn will present for 20 minutes, and 40 minutes will be dedicated to live questions and answers.
Date: Wednesday, September 15, 2021
Time: 3:30 pm ET - 4:30 pm ET
Access: https://goto.webcasts.com/starthere.jsp?ei=14...p;sti=cydy
Interested participants are encouraged to login early prior to the start of the event. This is a livestream presentation, and a link will also be posted on CytoDyn’s website within approximately 48 hours after the presentation. The conference sponsor provides corporate visibility services to CytoDyn for a fee.
, a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer and Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development of CytoDyn will provide a comprehensive business update at the upcoming Emerging Growth Conference. CytoDyn will present for 20 minutes, and 40 minutes will be dedicated to live questions and answers. Date: Wednesday, September 15, 2021
Time: 3:30 pm ET - 4:30 pm ET
Access: https://goto.webcasts.com/starthere.jsp?ei=14...p;sti=cydy
Interested participants are encouraged to login early prior to the start of the event. This is a livestream presentation, and a link will also be posted on CytoDyn’s website within approximately 48 hours after the presentation. The conference sponsor provides corporate visibility services to CytoDyn for a fee.
(2)
(0)
